A Phase 1 interventional study of Atogepant and Ubrogepant in Healthy Volunteers, sponsored by AbbVie. Completed at 3 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess adverse events and compare how ubrogepant and atogepant tablets move through the body of healthy adult lactating female participants.
Ubrogepant and atogepant are approved drugs for treatment of migraine in adults. Participants will be assigned to one of the 2 treatment arms to receive atogepant or ubrogepant. Approximately 24 healthy adult lactating female participants will be enrolled at 3 sites in the United States
Participants will receive oral tablets of ubrogepant or atogepant on Day 1 and will be followed for 30 days.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of atogepant on Day 1.
Drug: Atogepant
Participants will receive single dose of ubrogepant on Day 1.
Drug: Ubrogepant
Oral Tablet
Also known as: QULIPTA
Oral Tablet
Also known as: UBRELVY
Number of Participants Experiencing Adverse Events
An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Day 30
Maximum Observed Plasma Concentration (Cmax) of Atogepant
Cmax of Atogepant
Time frame: Up to Day 2
Maximum Observed Plasma Concentration (Cmax)of Ubrogepant
Cmax of Ubrogepant
Time frame: Up to Day 2
Time to Cmax (Tmax) of Atogepant
Tmax of Atogepant
Time frame: Up to Day 2
Time to Cmax (Tmax) of Ubrogepant
Tmax of Ubrogepant
Time frame: Up to Day 2
Apparent Terminal Phase Elimination Rate Constant (β) of Atogepant
Apparent terminal phase elimination rate constant of Atogepant
Time frame: Up to Day 2
Apparent Terminal Phase Elimination Rate Constant (β) of Ubrogepant
Apparent terminal phase elimination rate constant of Ubrogepant
Time frame: Up to Day 2
Terminal Phase Elimination Half-life (t1/2) of Atogepant
T1/2 of Atogepant
Time frame: Up to Day 2
Terminal Phase Elimination Half-life (t1/2) of Ubrogepant
T1/2 of Ubrogepant
Time frame: Up to Day 2
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Atogepant
AUCt of Atogepant
Time frame: Up to Day 2
AUCt of Ubrogepant
AUCt of Ubrogepant
Time frame: Up to Day 2
AUC From Time 0 to the Time Infinity (AUCinf) of Atogepant
AUCinf of Atogepant
Time frame: Up to Day 2
AUCinf of Ubrogepant
AUCinf of Ubrogepant
Time frame: Up to Day 2
Maximum Observed Breast Milk Concentration (CMAX) of Atogepant
CMAX of Atogepant
Time frame: Up to Day 2
Maximum Observed Breast Milk Concentration (CMAX) of Ubrogepant
CMAX of Ubrogepant
Time frame: Up to Day 2
Time to Maximum Observed Breast Milk Concentration (TMAX) of Atogepant
TMAX of Atogepant
Time frame: Up to Day 2
Time to Maximum Observed Breast Milk Concentration (TMAX) of Ubrogepant
TMAX of Ubrogepant
Time frame: Up to Day 2
Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCLST) of Atogepant
AUCLST of Atogepant
Time frame: Up to Day 2
Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCLST) of Ubrogepant
AUCLST of Ubrogepant
Time frame: Up to Day 2
Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCINF) of Atogepant
AUCINF of Atogepant
Time frame: Up to Day 2
Area Under the Milk Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCINF) of Ubrogepant
AUCINF of Ubrogepant
Time frame: Up to Day 2
Plan to share: No
Ran from Jul 2023 to primary completion in Feb 2024, 7 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atogepant